Podium to Practice: ESMO® 2025 – Lung: Safety Analysis of DeLLphi-304

Podium to Practice: ESMO® 2025 – Lung: Safety Analysis of DeLLphi-304

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barbara Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Peter Ellis

Studies / Trials Discussed

LBA100 – Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer

Studies/trials discussed:

LBA100 – Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
Tagged